A convergent model explains the signature loss of first-phase insulin and dampened pulsatility: impaired β-cell stimulus–secretion and identity, loss of normal paracrine interactions, and slowed hormone exchange from microvascular and ECM remodelling, overlaid by systemic factors (cachexia, hepatic insulin handling). The gene discussed is INS; the disease is Cachexia.